Debbie Rigby rounds up the latest in research news
A systematic review and meta-analysis of 42 studies has concluded that probiotics are effective in preventing antibiotic-associated diarrhoea in adults. Co-administration of probiotics with antibiotics reduces the risk of AAD in adults by 37%, with a number needed to treat of 20 patients. Higher dosages and certain species (Lactobacillus and Saccharomyces genera) have shown increased effectiveness.
BMJ Open 2021;11:e043054.
This expert review of SGLT2 inhibitors has concluded that they appear to be safe and effective agents that improve glycemia when used alone or in combination with any other approved antihyperglycemic medications. Other beneficial effects include reductions in body weight and blood pressure, improvements in renal outcomes, all-cause mortality, cardiovascular mortality and worsening heart failure.
Expert Opinion on Pharmacotherapy 2021.
In this article, the authors explore the existing evidence on dapagliflozin in heart failure with reduced ejection fraction (HFrEF), with or without diabetes. Dapagliflozin as an add-on therapy for patients with HFrEF significantly reduces the incidence of CV endpoints such as CV death and hospitalisation for heart failure. The safety of dapagliflozin in patients with eGFR as low as 25 mL/min/1.73 m2 has been shown.
Therapeutics and Clinical Risk Management 2021;17:823–830.
Around 5–10% of people with asthma suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. Four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL-5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody).
Asthma Research and Practice 2021;7:12.